Hedge fund manager J. Kyle Bass slammed US Patent & Trademark Office, after it blocked his attempt to challenge a patent held by drugmaker Biogen. The Patent Trial and Appeal Board, which is part of the USPTO, said on Tuesday that it was denying Bass' petition to review a patent for a multiple sclerosis drug licensed by Biogen.

Topics:     826 and    google   coalition   capital   ipwatchdog   congress   watch   chinese   americans   bass   biogen   the   uspto   insider   ipr   therapeutics   quinn   business   lee   group   patents   held   rejected   sclerosis   filed   early   activist   call   thursday   part   review   multiple   leads   pretty   challenging   stop   time   set   law   comment   strikes   balls   calling   tossed   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News